BioSpace News Archive

This Phase I clinical trial will assess the safety and tolerability of CTH120, which acts as a neuroplasticity modulator.

LeMaitre Vascular, Inc. announced that it is participating in two upcoming investor conferences in June.

ExThera Medical, a healthcare company that has developed and commercialized a unique extracorporeal blood filtration medical device, participated in the annual International Conference on Extracorporeal Organ Support.

ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT and MVR-T3011 IV in both U.S. and China with all selected to be published at the 2023 American Society for Clinical Oncology Annual Meeting taking place from June 2nd to 6th, 2023 in Chicago, IL.

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from “Idea to IND” (I to I™), today announced the appointment of Steve Arkinstall, D.Phil., as its Chief Scientific Advisor.

Cellusion Inc. announced that it has raised 2.83 billion yen in Series C Round financing.

NewAmsterdam Pharma Company N.V. announced the pricing of the previously announced underwritten public offering of 13,857,415 shares of the Company’s ordinary shares, with a nominal value of €0.12 per share by certain of the Company’s existing shareholders, including affiliates of Forbion Capital Partners, at a public offering price of $11.50 per share.

Ascentage Pharma announced that for the second consecutive year, it has released updated data of APG-2449, a novel FAK/ALK/ROS1 tyrosine kinase inhibitor developed by Ascentage Pharma, in patients with non-small cell lung cancer, in a Poster Discussion session at the 59th American Society of Clinical Oncology Annual Meeting.

Transgene and NEC Corporation announced that new data have been presented on TG4050, an individualized neoantigen cancer vaccine, at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities.

OSE Immunotherapeutics SA presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer and in ovarian cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2 - 6.